Design and statistical considerations for studies evaluating the efficacy of a single dose of the human papillomavirus (HPV) vaccine.
- Joshua N Sampson,
- Allan Hildesheim,
- Rolando Herrero,
- Paula Gonzalez,
- Aimee Kreimer,
- Mitchell H Gail
Contemp Clin Trials 2018 Feb 20. Epub 2018 Feb 20.
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 9609 Medical Center Drive, 7E594, Rockville, MD 20850, United States. Electronic address:
Cervical cancer is a leading cause of cancer mortality in women worldwide. Human papillomavirus (HPV) types 16 and 18 cause about 70% of all cervical cancers. Clinical trials have demonstrated that three doses of either commercially available HPV vaccine, Cervarix or Gardasil, prevent most new HPV 16/18 infections and associated precancerous lesions. Read More